Beyond diagnosis: What biomarkers are teaching us about the "bio"logy of Alzheimer disease

Annals of Neurology

Volumn 67, Issue 3, 2010, Pages 283-285

  Rabinovici, Gil D ^a,b   Roberson, Erik D ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CARBON 11; FLUORODEOXYGLUCOSE F 18; LIGAND; PITTSBURGH COMPOUND B C 11; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; AGING; ALZHEIMER DISEASE; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; EDITORIAL; HUMAN; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; BRAIN; COGNITION DISORDERS; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HUMANS; NEUROFIBRILLARY TANGLES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENILE PLAQUES; TAU PROTEINS;

EID: 77950524673     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22020     Document Type: Editorial

References (23)

1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-319.
2. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-613.
3. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-413.
4. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006;66:1837-1844.
5. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302:2557-2564.
6. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-2070.
7. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372: 216-223.
8. Chételat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and β-amyloid deposition in Alzheimer's disease. Ann Neurol 2010;66:000-000
9. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129:2856-2866.
10. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-1365.
11. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated β-amyloid deposition in elderly subjects. Brain 2009;132:1310-1323.
12. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665-680.
13. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 2009;19:497-510.
14. Sperling RA, Laviolette PS, O'Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009;63:178-188.
15. Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry 2010;67:584-587.
16. Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009;65:176-183.
17. Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009;66: 1469-1475.
18. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
19. Vemuri P, Wiste HJ, Weigand SD, et al. Effect of APOE on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 2010;67:122-131.
20. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009;106:6820-6825.
21. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-β but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (in press).
22. Kok E, Haikonen S, Luoto T, et al. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 2009;65:650-657.
23. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128.